<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03131492</url>
  </required_header>
  <id_info>
    <org_study_id>PR(AMI)68/2017</org_study_id>
    <nct_id>NCT03131492</nct_id>
  </id_info>
  <brief_title>Early Dehiscence Markers in Ovarian Cancer Surgery</brief_title>
  <acronym>EDMOCS</acronym>
  <official_title>Procalcitonin and C-Reactive Protein as Early Anastomotic Dehiscence Markers in Ovarian Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EDMOCS trial pretends to evaluate if C-reactive protein (CRP) and procalcitonin (PCT) can
      predict intestinal anastomotic leaks before early discharge in advanced ovarian cancer
      surgery requiring intestinal resection. These markers have already been positively tested in
      colorectal cancer surgery, but not yet in ovarian surgery.

      Patients undergoing intestinal resection in ovarian cancer surgery will be included.
      C-reactive protein and PCT will be measured pre-operatively, and on the second, fourth and
      sixth postoperative day. Thirty-day readmissions, re-operations and mortality will be
      recorded.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>Number of patients with anastomotic leak detected by elevation of C-reactive protein and procalcitonin levels</measure>
    <time_frame>Within the first 30 days after the surgery</time_frame>
    <description>To evaluate whether C-reactive protein (CRP) and procalcitonin (PCT) can predict anastomotic leak before early discharge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein and procalcitonin measures in patients without complications in ovarian surgery.</measure>
    <time_frame>Within the first six days after the surgery</time_frame>
    <description>Defining normal range values of C-Reactive Protein and Procalcitonin during postoperative ovarian cancer surgery.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ovarian Neoplasms Malignant</condition>
  <condition>Anastomotic Leak</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed of an advenced ovarian cancer who need an intestinal resection during
        ovarian surgery.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ovarian cancer stage III-IV

          -  Intestinal resection needed

        Exclusion Criteria:

          -  Infection diagnosed at time of surgery.

          -  Urgent surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Gil-Moreno, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Department of Obstetrics and Gynecology, Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Asunción Pérez-Benavente, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Unit of Gynecology Oncology Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Luis Sánchez-Iglesias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Morales, MD</last_name>
    <phone>660786261</phone>
    <email>claramcomas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>José Luis Sánchez-Iglesias, MD</last_name>
    <phone>650793139</phone>
    <email>jlsanig@yahoo.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melchor Carbonell, MD</last_name>
      <phone>0034626470597</phone>
      <email>xormd11@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Trencheva K, Morrissey KP, Wells M, Mancuso CA, Lee SW, Sonoda T, Michelassi F, Charlson ME, Milsom JW. Identifying important predictors for anastomotic leak after colon and rectal resection: prospective study on 616 patients. Ann Surg. 2013 Jan;257(1):108-13. doi: 10.1097/SLA.0b013e318262a6cd.</citation>
    <PMID>22968068</PMID>
  </reference>
  <reference>
    <citation>Almeida AB, Faria G, Moreira H, Pinto-de-Sousa J, Correia-da-Silva P, Maia JC. Elevated serum C-reactive protein as a predictive factor for anastomotic leakage in colorectal surgery. Int J Surg. 2012;10(2):87-91. doi: 10.1016/j.ijsu.2011.12.006. Epub 2011 Dec 28.</citation>
    <PMID>22222182</PMID>
  </reference>
  <reference>
    <citation>Lu Y, Huang S, Li P, Chen B, Liu W, Chen Z, Yin F. Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer. Exp Ther Med. 2015 May;9(5):2003-2007. Epub 2015 Mar 12.</citation>
    <PMID>26136929</PMID>
  </reference>
  <reference>
    <citation>Garcia-Granero A, Frasson M, Flor-Lorente B, Blanco F, Puga R, Carratalá A, Garcia-Granero E. Procalcitonin and C-reactive protein as early predictors of anastomotic leak in colorectal surgery: a prospective observational study. Dis Colon Rectum. 2013 Apr;56(4):475-83. doi: 10.1097/DCR.0b013e31826ce825.</citation>
    <PMID>23478615</PMID>
  </reference>
  <reference>
    <citation>Zawadzki M, Czarnecki R, Rzaca M, Obuszko Z, Velchuru VR, Witkiewicz W. C-reactive protein and procalcitonin predict anastomotic leaks following colorectal cancer resections - a prospective study. Wideochir Inne Tech Maloinwazyjne. 2016 Jan;10(4):567-73. doi: 10.5114/wiitm.2015.56999. Epub 2016 Jan 12.</citation>
    <PMID>26865894</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Anastomotic Leak</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

